Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

BACKGROUND: Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Belgiovine, Cristina, Bello, Ezia, Liguori, Manuela, Craparotta, Ilaria, Mannarino, Laura, Paracchini, Lara, Beltrame, Luca, Marchini, Sergio, Galmarini, Carlos M, Mantovani, Alberto, Frapolli, Roberta, Allavena, Paola, D'Incalci, Maurizio
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572168/
https://ncbi.nlm.nih.gov/pubmed/28683469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.205
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados